EUROPE RAT MODEL MARKET FORECAST 2017-2025
KEY FINDINGS
The Europe model market is expected to grow from $120948 thousand in 2016 to $272619 thousand by the year 2025 at an anticipated CAGR growth of 9.51% for the forecast year 2017-2025. Improving genome editing techniques, rapid increase and ease in availability of results in transgenic rats and a growing interest of biotech and pharma companies in the market are the major drivers for the boom in the rat model market.
MARKET INSIGHTS
The United Kingdom has the largest market share in the European market owing to a large number of fiscal investments in research areas and profitable research related schemes. The market is broadly segmented into 3 categories: by type, by component and by the application. On the basis of type, the outbred rat type is expected to dominate the Global Rat Model market with an expected growth at a CAGR of 11.36%. In terms of components, the services sector currently holds the largest market share although, the technology segment is anticipated to grow at a faster rate with a CAGR of 10.45% during the forecast period. The toxicology application is currently leading in the market but the oncology application is fast catching up and is expected to grow at a CAGR of 11.7 % during the forecast period.
COMPETITIVE INSIGHTS
Research scientists and top pharmaceutical companies are increasingly using rat models for medical as well as clinical research.The top companies using these models are Biomedical Research Model Inc., Laboratory Corporation Of America, Biomere, Transviragen, Inc., Clea Japan, Vivo Biotech Ltd, Cyagen Biosciences Inc., Oncodesign S.A., Hera Biolabs Inc, Transviragen Inc.,, Transposagen Biopharmaceuticals Inc, Charles River Laboratories Inc, Taconic Biosciences, Sage Labs Inc, Janvier Labs, Harlan Laboratories, Inc, Genoway S. A. and Covance Inc
The Europe model market is expected to grow from $120948 thousand in 2016 to $272619 thousand by the year 2025 at an anticipated CAGR growth of 9.51% for the forecast year 2017-2025. Improving genome editing techniques, rapid increase and ease in availability of results in transgenic rats and a growing interest of biotech and pharma companies in the market are the major drivers for the boom in the rat model market.
MARKET INSIGHTS
The United Kingdom has the largest market share in the European market owing to a large number of fiscal investments in research areas and profitable research related schemes. The market is broadly segmented into 3 categories: by type, by component and by the application. On the basis of type, the outbred rat type is expected to dominate the Global Rat Model market with an expected growth at a CAGR of 11.36%. In terms of components, the services sector currently holds the largest market share although, the technology segment is anticipated to grow at a faster rate with a CAGR of 10.45% during the forecast period. The toxicology application is currently leading in the market but the oncology application is fast catching up and is expected to grow at a CAGR of 11.7 % during the forecast period.
COMPETITIVE INSIGHTS
Research scientists and top pharmaceutical companies are increasingly using rat models for medical as well as clinical research.The top companies using these models are Biomedical Research Model Inc., Laboratory Corporation Of America, Biomere, Transviragen, Inc., Clea Japan, Vivo Biotech Ltd, Cyagen Biosciences Inc., Oncodesign S.A., Hera Biolabs Inc, Transviragen Inc.,, Transposagen Biopharmaceuticals Inc, Charles River Laboratories Inc, Taconic Biosciences, Sage Labs Inc, Janvier Labs, Harlan Laboratories, Inc, Genoway S. A. and Covance Inc
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. IMPROVEMENT IN GENOME EDITING
4.1.2. FAST AND INCREASING AVAILABILITY IN RAT TRANSGENIC
4.1.3. INCREASING PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES R&D
4.2. MARKET RESTRAINTS
4.2.1. PRACTICE OF ANIMALS IN RESEARCH IS CONSIDERED UNETHICAL
4.2.2. FLUCTUATING RULES AND REGULATION ON ANIMAL TESTING
4.2.3. USE OF ZEBRA FISH IN RESEARCH IS THE GROWING MODEL
4.2.4. IN VITRO AND ALTERNATIVE TESTING TECHNIQUES MODELS FOR RESEARCH
4.3. MARKET OPPORTUNITIES
4.3.1. RISING DEMAND OF RAT MODEL FOR RESEARCH ACTIVITIES FROM EMERGENT ECONOMIES
4.3.2. PERSONALIZED MEDICINE ESTABLISHED TO SURGE DEMAND
4.3.3. ESCALATION IN MONOCLONAL ANTIBODY CREATION
4.4. MARKET CHALLENGES
4.4.1. RAT MODEL IS HIGHLY EXPENSIVE
5. MARKET SEGMENTATION
5.1. BY RAT MODEL TYPES
5.1.1. INBRED RATS
5.1.2. KNOCKOUT/GENETICALLY ENGINEERED RATS
5.1.3. HYBRID/CONGENIC RATS
5.1.4. OUTBRED RATS
5.1.5. IMMUNE-DEFICIENT RATS
5.1.6. CONDITIONED/SURGICALLY MODIFIED RATS
5.2. BY COMPONENTS
5.2.1. TECHNOLOGY
5.2.1.1. NUCLEAR TRANSFERASE TECHNOLOGY
5.2.1.2. MICROINJECTION
5.2.1.3. EMBRYONIC STEM CELL INJECTION
5.2.1.4. OTHER TECHNOLOGIES
5.2.2. SERVICES
5.2.3. RAT CARE PRODUCTS
5.2.3.1. FEED
5.2.3.2. BEDDING
5.2.3.3. CAGES
5.2.3.4. OTHER CARE PRODUCTS
5.3. BY APPLICATION
5.3.1. DIABETES
5.3.2. TOXICOLOGY
5.3.3. ONCOLOGY
5.3.4. IMMUNOLOGY & INFLAMMATION
5.3.5. OTHER
6. KEY ANALYTICS
6.1. PORTERS 5 FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. VALUE CHAIN ANALYSIS
6.4. OPPORTUNITY MATRIX
6.5. REGULATORY FRAMEWORK
6.6. ESTIMATION ANALYSIS
6.6.1. GLOBAL BIOTECH INVESTMENT
6.6.2. BIOTECHNOLOGY FIRMS ACROSS COUNTRIES
6.6.3. GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT EXPENDITURE
6.6.4. GLOBAL BIOTECH R&D EXPENDITURE
6.7. KEY BUYING CRITERIA
6.7.1. HIGH ACCURACY
6.7.2. HIGH EFFICACY
6.7.3. QUALITY OF OPERATING PROCEDURE
6.7.4. PRICE
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE RAT MODEL MARKET
7.1.1. UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. REST OF EUROPE (ROE)
8. COMPETITIVE ANALYSIS
8.1. KEY STRATEGIES AND ANALYSIS
8.1.1. MERGER & ACQUISITION (M&A)
8.1.2. COLLABORATION & PARTNERSHIPS
8.1.3. INVESTMENT / PRODUCT LAUNCH
8.2. MARKET SHARE
8.3. TOP COMPANY ANALYSIS
8.4. LIST OF M&A
8.5. COLLABORATION & PARTNERSHIP
8.6. LIST OF PRODUCT LAUNCHES
9. COMPANY PROFILE
9.1. BIOMEDICAL RESEARCH MODEL INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.2. CHARLES RIVER LABORATORIES INC.
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. KEY INNOVATION SECTOR
9.2.4. STRATEGIC INITIATIVES
9.2.5. SCOT ANALYSIS
9.3. COVANCE INC. (LABCORP HOLDING COMPANY)
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. KEY INNOVATION SECTOR
9.3.4. STRATEGIC INITIATIVES
9.3.5. SCOT ANALYSIS
9.4. GENOWAY S. A.
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. KEY INNOVATION SECTOR
9.4.4. STRATEGIC INITIATIVES
9.4.5. SCOT ANALYSIS
9.5. HARLAN LABORATORIES, INC. (ENVIGO, INC. HOLDING COMPANY)
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.6. JANVIER LABS
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. SAGE LABS INC(HORIZON DISCOVERY GROUP PLC HOLDING COMPANY)
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVE
9.7.4. SCOT ANALYSIS
9.8. TACONIC BIOSCIENCES
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. KEY INNOVATION SECTOR
9.8.4. STRATEGIC INITIATIVES
9.8.5. SCOT ANALYSIS
9.9. TRANSPOSAGEN BIOPHARMACEUTICALS INC
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. KEY INNOVATION SECTOR
9.9.4. STRATEGIC INITIATIVES
9.9.5. SCOT ANALYSIS
9.10. TRANSVIRAGEN INC.
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. HERA BIOLABS INC.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. KEY INNOVATION SECTOR
9.11.4. STRATEGIC INITIATIVE
9.11.5. SCOT ANALYSIS
9.12. ONCODESIGN S.A.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. KEY INNOVATION SECTOR
9.12.4. STRATEGIC INITIATIVE
9.12.5. SCOT ANALYSIS
9.13. CYAGEN BIOSCIENCES INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. KEY INNOVATION SECTOR
9.13.4. STRATEGIC INITIATIVE
9.13.5. SCOT ANALYSIS
9.14. VIVO BIOTECH LTD.
9.14.1. COMPANY OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. CLEA JAPAN
9.15.1. COMPANY OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. KEY INNOVATION SECTOR
9.15.5. SCOT ANALYSIS
9.16. TRANSVIRAGEN, INC.
9.16.1. COMPANY OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVES
9.16.4. KEY INNOVATION SECTOR
9.16.5. SCOT ANALYSIS
9.17. BIOMERE
9.17.1. COMPANY OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVES
9.17.4. KEY INNOVATION SECTOR
9.17.5. SCOT ANALYSIS
9.18. LABORATORY CORPORATION OF AMERICA HOLDINGS
9.18.1. COMPANY OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. STRATEGIC INITIATIVES
9.18.4. KEY INNOVATION SECTOR
9.18.5. SCOT ANALYSIS
TABLE LIST
TABLE 1 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 2 BENEFITS OF RAT
TABLE 3 EUROPE RAT MODEL MARKET BY RAT TYPES 2017-2025 ($ THOUSAND)
TABLE 4 EXAMPLES OF INBRED RAT AND THERE RESEARCH APPLICATIONS
TABLE 5 EUROPE INBRED RAT TYPE 2017-2025 ($ THOUSAND)
TABLE 6 EUROPE GENETICALLY ENGINEERED RAT MARKET 2017-2025($ THOUSAND)
TABLE 7 EUROPE HYBRID RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 8 EXAMPLES OF OUTBRED RAT AND THERE RESEARCH APPLICATIONS
TABLE 9 EUROPE OUTBRED RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 10 EUROPE IMMUNE DEFICIT RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 11 EUROPE SURGICALLY MODIFIED RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 12 EUROPE RAT MODEL MARKET BY COMPONENTS 2017-2025 ($ THOUSAND)
TABLE 13 EUROPE RAT MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 14 EUROPE NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 15 EUROPE MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 16 EUROPE EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 17 EUROPE OTHER TECHNOLOGY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 18 EUROPE RAT MODEL SERVICES MARKET 2017-2025 ($ THOUSAND)
TABLE 19 EUROPE RAT MODEL MARKET BY RAT CARE PRODUCTS 2017-2025 ($ THOUSAND)
TABLE 20 EUROPE RAT FEED MARKET 2017-2025 ($ THOUSAND)
TABLE 21 POPULAR FOODS FOR RAT
TABLE 22 EUROPE RAT BEDDING MARKET 2017-2025 ($ THOUSAND)
TABLE 23 EUROPE RAT CAGES MARKET 2017-2025 ($ THOUSAND)
TABLE 24 EUROPE RAT CARE OTHERS MARKET 2017-2025 ($ THOUSAND)
TABLE 25 EUROPE RAT MODEL MARKET BY APPLICATION 2017-2025($ THOUSAND)
TABLE 26 EUROPE DIABETES RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 27 EUROPE ONCOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 28 EUROPE IMMUNOLOGY & INFLAMMATION RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 29 EUROPE OTHER RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE LIST
FIGURE 1 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 2 NUMBER OF EXPERIMENTAL PROCEDURES OF ANIMALS IN U.S. IN 2016
FIGURE 3 TOP COMPANIES BASED ON IN VITRO DIAGNOSTICS REVENUE IN 2016 ($ MILLION)
FIGURE 4 EUROPE RAT MODEL MARKET BY INBRED RAT TYPE 2017-2025 ($ THOUSAND)
FIGURE 5 EUROPE RAT MODEL MARKET BY GENETICALLY ENGINEERED RAT 2017-2025 ($ THOUSAND)
FIGURE 6 EUROPE RAT MODEL MARKET BY HYBRID RAT TYPE 2017-2025 ($ THOUSAND)
FIGURE 7 EUROPE RAT MODEL MARKET BY OUTBRED RAT 2017-2025 ($ THOUSAND)
FIGURE 8 EUROPE RAT MODEL MARKET BY IMMUNE DEFICIENT RAT 2017-2025 ($ THOUSAND)
FIGURE 9 EUROPE RAT MODEL MARKET BY SURGICALLY MODIFIED RAT 2017-2025 ($ THOUSAND)
FIGURE 10 EUROPE RAT MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSANDS)
FIGURE 11 EUROPE RAT MODEL MARKET BY NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 12 EUROPE RAT MODEL MARKET BY MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 13 EUROPE RAT MODEL MARKET BY EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 14 EUROPE RAT MODEL MARKET BY OTHER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 15 RAT CARE PRODUCTS BY TYPE 2016 (%)
FIGURE 16 EUROPE RAT CARE PRODUCT MARKET BY FEED 2017-2025 ($ THOUSAND)
FIGURE 17 EUROPE RAT CARE PRODUCT MARKET BY BEDDING 2017-2025 ($ THOUSAND)
FIGURE 18 EUROPE RAT CARE PRODUCT MARKET BY CAGES 2017-2025 ($ THOUSAND)
FIGURE 19 EUROPE RAT MODEL MARKET BY DIABETES 2017-2025($ THOUSAND)
FIGURE 20 PERCENTAGE OF DIABETES IN WORLD ADULT POPULATION IN 1980, 2015 AND 2040
FIGURE 21 EUROPE RAT MODEL MARKET BY TOXICOLOGY 2017-2025($ THOUSAND)
FIGURE 22 EUROPE TOXICOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 23 EUROPE RAT MODEL MARKET BY ONCOLOGY 2017-2025($ THOUSAND)
FIGURE 24 INCREASING COSTS OF ONCOLOGY THERAPEUTICS AND SUPPORTIVE CARE DRUGS ($ BILLION)
FIGURE 25 EUROPE RAT MODEL MARKET BY IMMUNOLOGY & INFLAMMATION 2017-2025 ($ THOUSAND)
FIGURE 26 EUROPE RAT MODEL MARKET BY OTHER 2017-2025 ($ THOUSAND)
FIGURE 27 PORTERS 5 FORCE MODEL OF RAT MODEL
FIGURE 28 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 29 UNITED KINGDOM RAT MODELS MARKET 2017-2025 ($ THOUSAND)
FIGURE 30 FRANCE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 31 GERMANY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 32 SPAIN RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 33 ITALY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 34 REST OF EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. IMPROVEMENT IN GENOME EDITING
4.1.2. FAST AND INCREASING AVAILABILITY IN RAT TRANSGENIC
4.1.3. INCREASING PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES R&D
4.2. MARKET RESTRAINTS
4.2.1. PRACTICE OF ANIMALS IN RESEARCH IS CONSIDERED UNETHICAL
4.2.2. FLUCTUATING RULES AND REGULATION ON ANIMAL TESTING
4.2.3. USE OF ZEBRA FISH IN RESEARCH IS THE GROWING MODEL
4.2.4. IN VITRO AND ALTERNATIVE TESTING TECHNIQUES MODELS FOR RESEARCH
4.3. MARKET OPPORTUNITIES
4.3.1. RISING DEMAND OF RAT MODEL FOR RESEARCH ACTIVITIES FROM EMERGENT ECONOMIES
4.3.2. PERSONALIZED MEDICINE ESTABLISHED TO SURGE DEMAND
4.3.3. ESCALATION IN MONOCLONAL ANTIBODY CREATION
4.4. MARKET CHALLENGES
4.4.1. RAT MODEL IS HIGHLY EXPENSIVE
5. MARKET SEGMENTATION
5.1. BY RAT MODEL TYPES
5.1.1. INBRED RATS
5.1.2. KNOCKOUT/GENETICALLY ENGINEERED RATS
5.1.3. HYBRID/CONGENIC RATS
5.1.4. OUTBRED RATS
5.1.5. IMMUNE-DEFICIENT RATS
5.1.6. CONDITIONED/SURGICALLY MODIFIED RATS
5.2. BY COMPONENTS
5.2.1. TECHNOLOGY
5.2.1.1. NUCLEAR TRANSFERASE TECHNOLOGY
5.2.1.2. MICROINJECTION
5.2.1.3. EMBRYONIC STEM CELL INJECTION
5.2.1.4. OTHER TECHNOLOGIES
5.2.2. SERVICES
5.2.3. RAT CARE PRODUCTS
5.2.3.1. FEED
5.2.3.2. BEDDING
5.2.3.3. CAGES
5.2.3.4. OTHER CARE PRODUCTS
5.3. BY APPLICATION
5.3.1. DIABETES
5.3.2. TOXICOLOGY
5.3.3. ONCOLOGY
5.3.4. IMMUNOLOGY & INFLAMMATION
5.3.5. OTHER
6. KEY ANALYTICS
6.1. PORTERS 5 FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. VALUE CHAIN ANALYSIS
6.4. OPPORTUNITY MATRIX
6.5. REGULATORY FRAMEWORK
6.6. ESTIMATION ANALYSIS
6.6.1. GLOBAL BIOTECH INVESTMENT
6.6.2. BIOTECHNOLOGY FIRMS ACROSS COUNTRIES
6.6.3. GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT EXPENDITURE
6.6.4. GLOBAL BIOTECH R&D EXPENDITURE
6.7. KEY BUYING CRITERIA
6.7.1. HIGH ACCURACY
6.7.2. HIGH EFFICACY
6.7.3. QUALITY OF OPERATING PROCEDURE
6.7.4. PRICE
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE RAT MODEL MARKET
7.1.1. UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. REST OF EUROPE (ROE)
8. COMPETITIVE ANALYSIS
8.1. KEY STRATEGIES AND ANALYSIS
8.1.1. MERGER & ACQUISITION (M&A)
8.1.2. COLLABORATION & PARTNERSHIPS
8.1.3. INVESTMENT / PRODUCT LAUNCH
8.2. MARKET SHARE
8.3. TOP COMPANY ANALYSIS
8.4. LIST OF M&A
8.5. COLLABORATION & PARTNERSHIP
8.6. LIST OF PRODUCT LAUNCHES
9. COMPANY PROFILE
9.1. BIOMEDICAL RESEARCH MODEL INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.2. CHARLES RIVER LABORATORIES INC.
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. KEY INNOVATION SECTOR
9.2.4. STRATEGIC INITIATIVES
9.2.5. SCOT ANALYSIS
9.3. COVANCE INC. (LABCORP HOLDING COMPANY)
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. KEY INNOVATION SECTOR
9.3.4. STRATEGIC INITIATIVES
9.3.5. SCOT ANALYSIS
9.4. GENOWAY S. A.
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. KEY INNOVATION SECTOR
9.4.4. STRATEGIC INITIATIVES
9.4.5. SCOT ANALYSIS
9.5. HARLAN LABORATORIES, INC. (ENVIGO, INC. HOLDING COMPANY)
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.6. JANVIER LABS
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. SAGE LABS INC(HORIZON DISCOVERY GROUP PLC HOLDING COMPANY)
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVE
9.7.4. SCOT ANALYSIS
9.8. TACONIC BIOSCIENCES
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. KEY INNOVATION SECTOR
9.8.4. STRATEGIC INITIATIVES
9.8.5. SCOT ANALYSIS
9.9. TRANSPOSAGEN BIOPHARMACEUTICALS INC
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. KEY INNOVATION SECTOR
9.9.4. STRATEGIC INITIATIVES
9.9.5. SCOT ANALYSIS
9.10. TRANSVIRAGEN INC.
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. HERA BIOLABS INC.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. KEY INNOVATION SECTOR
9.11.4. STRATEGIC INITIATIVE
9.11.5. SCOT ANALYSIS
9.12. ONCODESIGN S.A.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. KEY INNOVATION SECTOR
9.12.4. STRATEGIC INITIATIVE
9.12.5. SCOT ANALYSIS
9.13. CYAGEN BIOSCIENCES INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. KEY INNOVATION SECTOR
9.13.4. STRATEGIC INITIATIVE
9.13.5. SCOT ANALYSIS
9.14. VIVO BIOTECH LTD.
9.14.1. COMPANY OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. CLEA JAPAN
9.15.1. COMPANY OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. KEY INNOVATION SECTOR
9.15.5. SCOT ANALYSIS
9.16. TRANSVIRAGEN, INC.
9.16.1. COMPANY OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVES
9.16.4. KEY INNOVATION SECTOR
9.16.5. SCOT ANALYSIS
9.17. BIOMERE
9.17.1. COMPANY OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVES
9.17.4. KEY INNOVATION SECTOR
9.17.5. SCOT ANALYSIS
9.18. LABORATORY CORPORATION OF AMERICA HOLDINGS
9.18.1. COMPANY OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. STRATEGIC INITIATIVES
9.18.4. KEY INNOVATION SECTOR
9.18.5. SCOT ANALYSIS
TABLE LIST
TABLE 1 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 2 BENEFITS OF RAT
TABLE 3 EUROPE RAT MODEL MARKET BY RAT TYPES 2017-2025 ($ THOUSAND)
TABLE 4 EXAMPLES OF INBRED RAT AND THERE RESEARCH APPLICATIONS
TABLE 5 EUROPE INBRED RAT TYPE 2017-2025 ($ THOUSAND)
TABLE 6 EUROPE GENETICALLY ENGINEERED RAT MARKET 2017-2025($ THOUSAND)
TABLE 7 EUROPE HYBRID RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 8 EXAMPLES OF OUTBRED RAT AND THERE RESEARCH APPLICATIONS
TABLE 9 EUROPE OUTBRED RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 10 EUROPE IMMUNE DEFICIT RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 11 EUROPE SURGICALLY MODIFIED RAT MARKET 2017-2025 ($ THOUSAND)
TABLE 12 EUROPE RAT MODEL MARKET BY COMPONENTS 2017-2025 ($ THOUSAND)
TABLE 13 EUROPE RAT MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 14 EUROPE NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 15 EUROPE MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 16 EUROPE EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 17 EUROPE OTHER TECHNOLOGY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 18 EUROPE RAT MODEL SERVICES MARKET 2017-2025 ($ THOUSAND)
TABLE 19 EUROPE RAT MODEL MARKET BY RAT CARE PRODUCTS 2017-2025 ($ THOUSAND)
TABLE 20 EUROPE RAT FEED MARKET 2017-2025 ($ THOUSAND)
TABLE 21 POPULAR FOODS FOR RAT
TABLE 22 EUROPE RAT BEDDING MARKET 2017-2025 ($ THOUSAND)
TABLE 23 EUROPE RAT CAGES MARKET 2017-2025 ($ THOUSAND)
TABLE 24 EUROPE RAT CARE OTHERS MARKET 2017-2025 ($ THOUSAND)
TABLE 25 EUROPE RAT MODEL MARKET BY APPLICATION 2017-2025($ THOUSAND)
TABLE 26 EUROPE DIABETES RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 27 EUROPE ONCOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 28 EUROPE IMMUNOLOGY & INFLAMMATION RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 29 EUROPE OTHER RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE LIST
FIGURE 1 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 2 NUMBER OF EXPERIMENTAL PROCEDURES OF ANIMALS IN U.S. IN 2016
FIGURE 3 TOP COMPANIES BASED ON IN VITRO DIAGNOSTICS REVENUE IN 2016 ($ MILLION)
FIGURE 4 EUROPE RAT MODEL MARKET BY INBRED RAT TYPE 2017-2025 ($ THOUSAND)
FIGURE 5 EUROPE RAT MODEL MARKET BY GENETICALLY ENGINEERED RAT 2017-2025 ($ THOUSAND)
FIGURE 6 EUROPE RAT MODEL MARKET BY HYBRID RAT TYPE 2017-2025 ($ THOUSAND)
FIGURE 7 EUROPE RAT MODEL MARKET BY OUTBRED RAT 2017-2025 ($ THOUSAND)
FIGURE 8 EUROPE RAT MODEL MARKET BY IMMUNE DEFICIENT RAT 2017-2025 ($ THOUSAND)
FIGURE 9 EUROPE RAT MODEL MARKET BY SURGICALLY MODIFIED RAT 2017-2025 ($ THOUSAND)
FIGURE 10 EUROPE RAT MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSANDS)
FIGURE 11 EUROPE RAT MODEL MARKET BY NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 12 EUROPE RAT MODEL MARKET BY MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 13 EUROPE RAT MODEL MARKET BY EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 14 EUROPE RAT MODEL MARKET BY OTHER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 15 RAT CARE PRODUCTS BY TYPE 2016 (%)
FIGURE 16 EUROPE RAT CARE PRODUCT MARKET BY FEED 2017-2025 ($ THOUSAND)
FIGURE 17 EUROPE RAT CARE PRODUCT MARKET BY BEDDING 2017-2025 ($ THOUSAND)
FIGURE 18 EUROPE RAT CARE PRODUCT MARKET BY CAGES 2017-2025 ($ THOUSAND)
FIGURE 19 EUROPE RAT MODEL MARKET BY DIABETES 2017-2025($ THOUSAND)
FIGURE 20 PERCENTAGE OF DIABETES IN WORLD ADULT POPULATION IN 1980, 2015 AND 2040
FIGURE 21 EUROPE RAT MODEL MARKET BY TOXICOLOGY 2017-2025($ THOUSAND)
FIGURE 22 EUROPE TOXICOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 23 EUROPE RAT MODEL MARKET BY ONCOLOGY 2017-2025($ THOUSAND)
FIGURE 24 INCREASING COSTS OF ONCOLOGY THERAPEUTICS AND SUPPORTIVE CARE DRUGS ($ BILLION)
FIGURE 25 EUROPE RAT MODEL MARKET BY IMMUNOLOGY & INFLAMMATION 2017-2025 ($ THOUSAND)
FIGURE 26 EUROPE RAT MODEL MARKET BY OTHER 2017-2025 ($ THOUSAND)
FIGURE 27 PORTERS 5 FORCE MODEL OF RAT MODEL
FIGURE 28 EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 29 UNITED KINGDOM RAT MODELS MARKET 2017-2025 ($ THOUSAND)
FIGURE 30 FRANCE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 31 GERMANY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 32 SPAIN RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 33 ITALY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 34 REST OF EUROPE RAT MODEL MARKET 2017-2025 ($ THOUSAND)
